NASDAQ:AMGN

Amgen Stock Forecast, Price & News

Trending Stocks Most-Downgraded Stocks

$226.91

+0.35 (+0.15 %)

(As of 12/3/2020 12:00 AM ET)

Add

Compare

Today's Range

$225.52

Now: $226.91▼

$228.45

50-Day Range

$216.38

MA: $228.00▼

$241.60

52-Week Range

$177.05

Now: $226.91▼

$264.97

Volume1.97 million shs

Average Volume2.84 million shs

Market Capitalization$132.10 billion

P/E Ratio18.30

Dividend Yield2.82%

Beta0.76

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 15 buy ratings, 12 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $254.08, Amgen has a forecasted upside of 12.0% from its current price of $226.91.
Amount of Analyst Coverage
Amgen has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Amgen has received 1,423 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amgen has received 949 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amgen has received 59.99% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote “Outperform” if you believe AMGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Amgen pays a meaningful dividend of 2.82%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amgen has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Amgen is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 37.65% next year. This indicates that Amgen will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,600.00 in company stock.
Percentage Held by Insiders
Only 0.36% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
71.72% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 5.26% in the coming year, from $16.15 to $17.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 18.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.74.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 18.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.54.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 1.90. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 12.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.46 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:AMGN

Previous Symbol

CUSIP03116210

CIK318154

Webwww.amgen.com

Phone805-447-1000

Employees23,400

Debt

Debt-to-Equity Ratio3.12

Current Ratio2.28

Quick Ratio1.88

Price-To-Earnings

Trailing P/E Ratio18.30

Forward P/E Ratio14.05

P/E Growth1.9

Sales & Book Value

Annual Sales$23.36 billion

Price / Sales5.65

Cash Flow$19.33 per share

Price / Cash Flow11.74

Book Value$18.82 per share

Price / Book12.06

Profitability

EPS (Most Recent Fiscal Year)$14.82

Net Income$7.84 billion

Net Margins29.42%

Return on Equity95.55%

Return on Assets15.52%

Miscellaneous

Outstanding Shares582,169,000

Market Cap$132.10 billion

Next Earnings Date2/4/2021 (Estimated)

OptionableOptionable

$226.91

+0.35 (+0.15 %)

(As of 12/3/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by Coronavirus?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 14.2% and is now trading at $226.91.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Amgen?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 12 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Amgen?

Wall Street analysts have given Amgen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings results on Monday, November, 2nd. The medical research company reported $4.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.75 by $0.62. The medical research company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.38 billion. Amgen had a return on equity of 95.55% and a net margin of 29.42%.
View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, October 21st. Investors of record on Monday, November 16th will be paid a dividend of $1.60 per share on Tuesday, December 8th. This represents a $6.40 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Friday, November 13th.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Wednesday, October, 28th. The company provided EPS guidance of $15.80-16.15 for the period, compared to the Thomson Reuters consensus estimate of $15.78. The company issued revenue guidance of $25.1-25.5 billion, compared to the consensus revenue estimate of $25.39 billion.

What price target have analysts set for AMGN?

28 brokers have issued 1 year price objectives for Amgen's stock. Their forecasts range from $185.00 to $304.00. On average, they expect Amgen's stock price to reach $254.08 in the next year. This suggests a possible upside of 12.0% from the stock's current price.
View analysts' price targets for Amgen.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
View all competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Who are Amgen's key executives?

Amgen's management team includes the following people:

Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 57, Pay $5.61M)
Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 59, Pay $2.44M)
Dr. David M. Reese M.D., Exec. VP of R&D (Age 57, Pay $2.54M)
Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 53, Pay $2.66M)
Mr. Peter H. Griffith, Exec. VP & CFO (Age 61)
Mr. Esteban Santos, Exec. VP of Operations (Age 52)
Ms. Linda H. Louie, VP of Fin. & Chief Accounting Officer
Mr. Mike Zahigian, Sr. VP & Chief Information Officer
Mr. Arvind Sood, VP of Investor Relations
Nancy A. Grygiel, Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.24%), State Street Corp (5.37%), Morgan Stanley (1.47%), Nuveen Asset Management LLC (0.69%), UBS Asset Management Americas Inc. (0.57%) and Charles Schwab Investment Management Inc. (0.47%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Allianz Asset Management GmbH, CIBC Private Wealth Group LLC, O Shaughnessy Asset Management LLC, AQR Capital Management LLC, Coho Partners Ltd., and LSV Asset Management. Company insiders that have sold Amgen company stock in the last year include David Piacquad, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, California Public Employees Retirement System, Morgan Stanley, DekaBank Deutsche Girozentrale, Candriam Luxembourg S.C.A., State of Tennessee Treasury Department, ProShare Advisors LLC, and Capital Wealth Planning LLC.
View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $226.91.

How big of a company is Amgen?

Amgen has a market capitalization of $132.10 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings